Abstract
Publications and patents relative to newly observed functions of β-(1,3)-D-glucans have notably increased in the last few years with the exploitation of their biological activities. The term β-(1,3)-D-glucans includes a very large number of polysaccharides from bacterial, fungal and vegetable sources. Their structures have a common backbone of β-(1,3) linked glucopyranosyl residues but the polysaccharidic chain can be β-(1,6) branched with glucose or integrate some β- (1,4) linked glucopyranosyl residues in the main chain. Except for the curdlan, a bacterial linear β-(1,3)-D-glucans, and for the scleroglucan produced by Sclerotium rolfsii, the main drawback limiting the development of these polysaccharides is the lack of efficient processes for their extraction and purification and their cost. However new applications in agronomy, foods, cosmetic and therapeutic could in a next future accentuate the effort of research for their development. So this review focuses on these β-(1,3)-D-glucans with the objective to detail the strategies employed for their extraction and the relation structure-functions identified when they induce biological activities.
Keywords: Polysaccharides, oligosaccharides, curdlan, glucan, biopolymer
Recent Patents on Biotechnology
Title: New Developments and Prospective Applications for β (1,3) Glucans
Volume: 1 Issue: 1
Author(s): Celine Laroche and Philippe Michaud
Affiliation:
Keywords: Polysaccharides, oligosaccharides, curdlan, glucan, biopolymer
Abstract: Publications and patents relative to newly observed functions of β-(1,3)-D-glucans have notably increased in the last few years with the exploitation of their biological activities. The term β-(1,3)-D-glucans includes a very large number of polysaccharides from bacterial, fungal and vegetable sources. Their structures have a common backbone of β-(1,3) linked glucopyranosyl residues but the polysaccharidic chain can be β-(1,6) branched with glucose or integrate some β- (1,4) linked glucopyranosyl residues in the main chain. Except for the curdlan, a bacterial linear β-(1,3)-D-glucans, and for the scleroglucan produced by Sclerotium rolfsii, the main drawback limiting the development of these polysaccharides is the lack of efficient processes for their extraction and purification and their cost. However new applications in agronomy, foods, cosmetic and therapeutic could in a next future accentuate the effort of research for their development. So this review focuses on these β-(1,3)-D-glucans with the objective to detail the strategies employed for their extraction and the relation structure-functions identified when they induce biological activities.
Export Options
About this article
Cite this article as:
Laroche Celine and Michaud Philippe, New Developments and Prospective Applications for β (1,3) Glucans, Recent Patents on Biotechnology 2007; 1 (1) . https://dx.doi.org/10.2174/187220807779813938
DOI https://dx.doi.org/10.2174/187220807779813938 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Boswellia serrata on Rat Trachea Contractility In Vitro
The Natural Products Journal Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Possible Predictive Value of Maspin Expression in Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery Further Vitamin D Analogs
Current Vascular Pharmacology Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging EDITORIAL (Thematic Issue: Brain Gut Axis-New View)
Current Neuropharmacology Update of Peptides with Antibacterial Activity
Current Medicinal Chemistry Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones
Current Pharmaceutical Biotechnology Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers PET-MRI Based Molecular Imaging as a Response Marker in Cervical Cancer: A Systematic Review
Current Molecular Imaging (Discontinued) Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy